Loading...
•
Jun 30, 2023
Lianbio-Adr Q2 2023 Earnings Report
LianBio's financial performance in Q2 2023 reflected a decrease in research and development expenses, offset by increased general and administrative costs, resulting in a reduced net loss compared to the same period last year.
Key Takeaways
LianBio reported a net loss of $21.6 million for the second quarter of 2023, compared to a net loss of $42.4 million for the second quarter of 2022. Research and development expenses decreased to $9.5 million from $28.6 million year-over-year, while general and administrative expenses increased slightly to $15.6 million from $14.6 million year-over-year. The company's cash, cash equivalents, and marketable securities totaled $267.3 million, providing a cash runway into the first half of 2025.
Mavacamten NDA under priority review with China NMPA.
Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with oHCM met the primary endpoint.
Data from EXPLORER-CN trial to be presented at the European Society of Cardiology Congress 2023.
Cash, cash equivalents, and marketable securities totaled $267.3 million, providing a runway into the first half of 2025.
Forward Guidance
LianBio anticipates several key milestones, including the potential NDA approval and commercial launch of mavacamten in China, topline data from the Phase 3 LIBRA trial of TP-03, and initiation of a pivotal Phase 2 trial of infigratinib. These steps are expected to drive growth and expand treatment options of cardiovascular, oncology, ophthalmology, and inflammatory disease indications.
Positive Outlook
- Initiating Phase 3 ODYSSEY-HCM trial of mavacamten in non-obstructive HCM in China in mid-2024.
- Anticipating NDA approval for mavacamten in China in mid-2024 and commercial launch in the second half of 2024.
- Expecting to launch mavacamten in Singapore and Macau in the fourth quarter of 2023.
- Planning to file NDAs to support mavacamten approval in Taiwan and Thailand in the fourth quarter of 2023.
- Expecting to report topline data from the Phase 3 LIBRA trial of TP-03 in Chinese patients with Demodex blepharitis in the fourth quarter of 2023.
Challenges Ahead
- Clinical trials may not produce expected results.
- Regulatory approvals are subject to uncertainty and delays.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...